Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS, UMR 8601, Université de Paris, F-75006 Paris, France.
Laboratoire des Biomolécules, LBM, Sorbonne Université, École Normale Supérieure, PSL University, CNRS, F-75005 Paris, France.
J Med Chem. 2020 Aug 13;63(15):8231-8249. doi: 10.1021/acs.jmedchem.9b02119. Epub 2020 Jul 15.
Sialin, encoded by the gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy. It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against -glycolylneuraminic acid in humans. Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies. The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an -linked aromatic or heteroaromatic substituent, and a hydrophobic side chain. The most potent compound, (LSP12-3129), inhibited -acetylneuraminic acid (Neu5Ac) transport in a non-competitive manner with IC ≈ 2.5 μM, a value 400-fold lower than the for Neu5Ac. In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation. Moreover, compound rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease. This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
唾液酸转运蛋白(Sialin)由 SLC17A5 基因编码,是 Salla 病(一种罕见的遗传性脑白质营养不良)中溶酶体唾液酸转运蛋白缺陷的原因。它还能使外源性唾液酸进行代谢掺入,导致人类产生针对β-酮基-N-乙酰神经氨酸的自身抗体。在这里,我们通过虚拟筛选和构效关系研究鉴定了一类新型人源唾液酸转运蛋白配体。该配体骨架的特征是具有游离羧基、β-连接的芳基或杂芳基取代基以及疏水性侧链的氨基酸主链。最有效的化合物 (LSP12-3129)以非竞争性方式抑制β-乙酰神经氨酸(Neu5Ac)的转运,IC ≈ 2.5 μM,值比 Neu5Ac 的低 400 倍。体外和分子对接研究表明,非竞争性特征归因于选择性抑制剂以面向细胞质的构象结合到 Neu5Ac 结合位点。此外,化合物 可挽救导致 Salla 病的致病性突变体(R39C)的运输缺陷。这种新型细胞通透抑制剂为研究唾液酸转运蛋白的生理作用提供了工具,并有助于开发 Salla 病的药理学伴侣。